• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Immunome Inc.

    3/19/25 5:10:27 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMNM alert in real time by email
    S-8 1 tm259725d2_s8.htm S-8

    As filed with the Securities and Exchange Commission on March 19, 2025

    Registration No. 333-

     

     

     

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    IMMUNOME, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   77-0694340
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    18702 N. Creek Parkway, Suite 100

    Bothell, WA 98011

    (Address of Principal Executive Offices)

     

    Immunome, Inc. 2020 Equity Incentive Plan

    Immunome, Inc. 2020 Employee Stock Purchase Plan

    Immunome, Inc. 2024 Inducement Plan

    (Full titles of the plans)

     

    Clay Siegall, Ph.D.

    Chief Executive Officer

    Immunome, Inc.

    18702 N. Creek Parkway, Suite 100

    Bothell, WA 98011

    (425) 939-7410

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Thomas A. Coll, Esq.

    Carlos Ramirez, Esq.

    Dylan Kornbluth, Esq.

    Cooley LLP

    10265 Science Center Drive

    San Diego, California 92121

    Tel: (858) 550-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨   Accelerated filer ¨
             
    Non-accelerated filer x   Smaller reporting company x
             
          Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This registration statement on Form S-8 (this “Registration Statement”) registers an aggregate of 5,223,041 shares of common stock, par value $0.0001 per share (“common stock”), of Immunome, Inc. (the “Registrant”) consisting of (i) 2,578,433 additional shares issuable under the Registrant’s 2020 Equity Incentive Plan (the “2020 Plan”) effective January 1, 2025, by operation of the 2020 Plan’s “evergreen” provision, (ii) 644,608 additional shares issuable under the Registrant’s 2020 Employee Stock Purchase Plan (the “2020 ESPP”) effective January 1, 2025, by operation of the 2020 ESPP’s “evergreen” provision, and (iii) 2,000,000 shares issuable under the Registrant’s 2024 Inducement Plan (the “Inducement Plan”).

     

    Pursuant to General Instruction E to Form S-8, and only with respect to the common stock being registered under the 2020 Plan and 2020 ESPP, this Registration Statement incorporates by reference the Registrant’s registration statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on March 25, 2021 (File No. 333-254731), March 16, 2023 (File No. 333-270598), and February 2, 2024 (File No. 333-276839), in each case as relating to the 2020 Plan and 2020 ESPP, and except to the extent supplemented, amended or superseded by the information set forth herein.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended (the “Securities Act”), and the instructions to Form S-8. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

     

    (a)The registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 19, 2025;
    (b)The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K from the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 26, 2024;
    (c)The Registrant’s Current Reports on Form 8-K filed with the Commission on January 23, 2025, January 29, 2025, and January 30, 2025; and
    (d)The description of the Registrant’s Common Stock set forth in the Registration Statement on Form 8-A filed with the Commission on September 30, 2020, including any amendments or reports filed for the purpose of updating such description.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information, or portions thereof, which are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

     

     

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 145 of the General Corporation Law of the State of Delaware (the “DGCL”) provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent of the Registrant. The DGCL provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaws, agreement, vote of stockholders or disinterested directors or otherwise. The Registrant’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws provide for indemnification by the Registrant of its directors and officers to the fullest extent permitted by the DGCL.

     

    Section 102(b)(7) of the DGCL permits a corporation to provide in its Amended and Restated Certificate of Incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (1) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (2) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) for unlawful payments of dividends or unlawful stock repurchases redemptions or other distributions or (4) for any transaction from which the director derived an improper personal benefit. The Registrant’s Amended and Restated Certificate of Incorporation provides for such limitation of liability to the fullest extent permitted by the DGCL.

     

    The Registrant has entered into indemnification agreements with each of its directors and executive officers to provide contractual indemnification in addition to the indemnification provided in our Amended and Restated Certificate of Incorporation. Each indemnification agreement provides for indemnification and advancements by the Registrant of certain expenses and costs relating to claims, suits or proceedings arising from his or her service to the Registrant or, at our request, service to other entities, as officers or directors to the maximum extent permitted by applicable law. We believe that these provisions and agreements are necessary to attract qualified directors.

     

    The Registrant also maintains standard policies of insurance under which coverage is provided (1) to its directors and officers against loss arising from claims made by reason of breach of duty or other wrongful act, while acting in their capacity as directors and officers of the Registrant and (2) to the Registrant with respect to payments which may be made by the Registrant to such officers and directors pursuant to any indemnification provision contained in the Registrant’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws or otherwise as a matter of law.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

     

     

     

    Item 8. Exhibits.

     

    Exhibit 
    Number
      Description
    4.1   Amended and Restated Certificate of Incorporation of the Registrant (Filed as Exhibit 3.1 to Registrant’s Current Report on Form 8-K filed with the Commission on October 6, 2020 and incorporated herein by reference).
    4.2   Certificate of Amendment, dated October 2, 2023 to the Amended and Restated Certificate of Incorporation of Immunome, Inc. to implement Officer Exculpation (Filed as Exhibit 3.3 to the Registrant’s Current Report on Form 8-K filed with the Commission on October 4, 2023 and incorporated herein by reference).
    4.3   Certificate of Amendment, dated October 2, 2023 to the Amended and Restated Certificate of Incorporation of Immunome, Inc. to implement the Authorized Share Increase (Filed as Exhibit 3.4 to the Registrant’s Current Report on Form 8-K filed with the Commission on October 4, 2023 and incorporated herein by reference).
    4.4   Amended and Restated Bylaws of the Registrant (Filed as Exhibit 3.2 to Registrant’s Current Report on Form 8-K filed with the Commission on October 6, 2020 and incorporated herein by reference).
    4.5   Form of Common Stock Certificate (Filed as Exhibit 4.2 to Amendment No. 1 to Registrant’s Registration Statement on Form S-1/A filed on September 24, 2020 and incorporated herein by reference).
    5.1*   Opinion of Cooley LLP.
    23.1*   Consent of Independent Registered Public Accounting Firm.
    23.2*   Consent of Cooley LLP (included in Exhibit 5.1).
    24.1*   Power of Attorney (included on signature page).
    99.1+   Immunome, Inc. 2020 Equity Incentive Plan (Filed as Exhibit 10.6 to Amendment No. 1 to Registrant’s Registration Statement on Form S-1/A filed with the Commission on September 24, 2020 and incorporated herein by reference).
    99.2+   Forms of Executive and Non-Executive Stock Option Grant Notice, Option Agreement and Notice of Exercise for the 2020 Equity Incentive Plan (Filed as Exhibit 10.7 to Registrant’s Annual Report on Form 10-K filed with the Commission on March 19, 2025 and incorporated herein by reference).
    99.3+   Immunome, Inc. 2020 Employee Stock Purchase Plan (Filed as Exhibit 10.8 to Amendment No. 1 to Registrant’s Registration Statement on Form S-1/A filed with the Commission on September 24, 2020 and incorporated herein by reference).
    99.4+   Forms of Executive and Non-Executive Stock Option Grant Notice, Option Agreement and Notice of Exercise for the 2024 Inducement Plan (Filed as Exhibit 10.11 to Registrant’s Current Report on Form 10-K filed with the Commission on March 19, 2025 and incorporated herein by reference).
    107*   Filing Fee Table.

     

    * Filed herewith.

    + Denotes management contract or compensatory plan or arrangement.

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;

     

     

     

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bothell, State of Washington, on March 19, 2025.

     

      IMMUNOME, INC.
         
      By:

    /s/ Clay Siegall

        Clay Siegall, Ph.D.
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Clay Siegall, Ph.D. and Max Rosett, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature   Title   Date
         
    /s/ Clay Siegall   President, Chief Executive Officer and Chairman of the Board of Directors   March 19, 2025
    Clay Siegall, Ph.D.   (Principal Executive Officer)    
             
    /s/ Max Rosett   Chief Financial Officer   March 19, 2025
    Max Rosett   (Principal Financial and Accounting Officer)    
             

    /s/ Isaac Barchas

      Director   March 19, 2025
    Isaac Barchas        
             
    /s/ Jean-Jacques Bienaimé   Director   March 19, 2025
    Jean-Jacques Bienaimé        
             
    /s/ James Boylan   Director   March 19, 2025
    James Boylan        
             
    /s/ Carol Schafer   Director   March 19, 2025
    Carol Schafer        
             
    /s/ Sandra Swain   Director   March 19, 2025
    Sandra M. Swain, M.D.        
             
    /s/ Philip Wagenheim   Director   March 19, 2025
    Philip Wagenheim        

     

     

     

    Get the next $IMNM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMNM

    DatePrice TargetRatingAnalyst
    12/1/2025$36.00Buy
    Truist
    9/22/2025$26.00Buy
    Goldman
    9/5/2025$26.00Buy
    Craig Hallum
    4/2/2025$23.00Buy
    Lake Street
    11/8/2024$30.00Overweight
    Stephens
    5/31/2024$27.00Overweight
    Piper Sandler
    4/30/2024$24.00Overweight
    JP Morgan
    4/15/2024$35.00Buy
    Guggenheim
    More analyst ratings

    $IMNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Siegall Clay B bought $100,018 worth of shares (4,729 units at $21.15), increasing direct ownership by 0.72% to 665,254 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/30/25 6:47:24 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Barchas Isaac sold $8,330,080 worth of shares (383,200 units at $21.74) (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/23/25 4:41:35 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Higgins Jack gifted 3,000 shares and received a gift of 3,000 shares, decreasing direct ownership by 7% to 37,729 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/22/25 7:43:46 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Immunome with a new price target

    Truist initiated coverage of Immunome with a rating of Buy and set a new price target of $36.00

    12/1/25 8:29:07 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Immunome with a new price target

    Goldman initiated coverage of Immunome with a rating of Buy and set a new price target of $26.00

    9/22/25 8:31:23 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on Immunome with a new price target

    Craig Hallum initiated coverage of Immunome with a rating of Buy and set a new price target of $26.00

    9/5/25 7:54:02 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $IMNM
    SEC Filings

    View All

    $IMNM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    President and CEO Siegall Clay B bought $100,018 worth of shares (4,729 units at $21.15), increasing direct ownership by 0.72% to 665,254 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/30/25 6:47:24 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Siegall Clay B bought $149,053 worth of shares (7,278 units at $20.48) and gifted 200,000 shares, decreasing direct ownership by 23% to 660,525 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/22/25 7:38:54 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Technical Officer Tsai Philip bought $204,900 worth of shares (10,000 units at $20.49), increasing direct ownership by 30% to 43,300 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/22/25 7:32:54 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Immunome Inc.

    8-K - Immunome Inc. (0001472012) (Filer)

    12/17/25 4:49:25 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Immunome Inc.

    424B5 - Immunome Inc. (0001472012) (Filer)

    12/17/25 4:45:40 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Immunome Inc.

    424B5 - Immunome Inc. (0001472012) (Filer)

    12/15/25 4:24:35 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 2, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 30,000 shares of common stock to one new employee under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $

    2/5/26 4:00:00 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The $71 Billion Cancer Shift: Why The FDA Is Speeding Up

    VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away from broad chemotherapy and toward precision biologics like mRNA and oncolytic viruses. The FDA is actively accelerating this cycle, having granted multiple breakthrough designations in January 2026 alone for platforms that demonstrate genuine survival durability[2]. This structural realignment positions Oncolytics Biotech Inc. (NASDAQ:ONCY), Moderna (NASDAQ:MRNA), Immunome (NASDAQ:IMNM), Autolus Therapeutics (NASDAQ:AUTL), and Prelude Therapeutics (NASDAQ:PRLD) within the emerging biological innovation c

    2/5/26 9:26:03 AM ET
    $AUTL
    $IMNM
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

    Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at Guggenheim's Emerging Outlook: Biotech Summit on February 11, 2026, at 9 a.m. ET. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days. About Immunome, Inc. Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer ther

    2/4/26 8:00:00 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNM
    Financials

    Live finance-specific insights

    View All

    Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

    Registrational trial met primary endpoint, with varegacestat significantly improving progression-free survival vs. placebo (hazard ratio = 0.16, p<0.0001) Trial also met all key secondary endpoints, with varegacestat delivering an objective response rate of 56% Varegacestat was generally well tolerated with a manageable safety profile New Drug Application submission to U.S. FDA planned for Q2 2026 Company to host conference call today at 8:30 a.m. ET Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacest

    12/15/25 7:00:00 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

    Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, in patients with progressing desmoid tumors. Webcast, Presentation Slides and Conference Call Information Immunome will host a webcast and conference call on Monday, December 15, 2025, at 8:30 a.m. ET / 5:30 a.m. PT to disc

    12/14/25 4:00:00 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ASP Isotopes Inc. and IsoBio, Inc. Announce Series Seed Funding of IsoBio, Inc. to Advance Innovative Antibody-Isotope Conjugates (AICsTM) For Cancer Treatment

    - IsoBio, Inc. (IsoBio) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates (AICsTM), targeting both derisked and novel tumor antigens for patients in need of new cancer therapies. - IsoBio has closed its initial Series Seed financing round, raising $5 million from ASP Isotopes Inc. (ASPI). - The strategic collaboration contemplates future manufacturing opportunities for PET Labs (ASPI's nuclear medicine subsidiary). - IsoBio plans to leverage the technology and global manufacturing capabilities developed by ASPI to reduce the uncertainty of isotope supply chain/manufacturi

    7/28/25 8:31:17 AM ET
    $ASPI
    $IMNM
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNM
    Leadership Updates

    Live Leadership Updates

    View All

    OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

    PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS

    8/6/25 7:00:00 AM ET
    $IMNM
    $INSM
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer

    Co-founder Susan Dillon, Ph.D., to remain as the chair of Board of Directors Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) medicines, today announced that its co-founder, Susan Dillon, Ph.D., will transition from her position as president and chief executive officer (CEO) and continue as chair of the Board of Directors and advisor to the company. As part of the planned leadership transition, Aro appointed industry veteran Purnanand Sarma, Ph.D., as the CEO and a member of the Board, effective immediately. "We founded Aro with the vision to create a new class of targeted siRNA medicines to address significant

    2/11/25 8:30:00 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunome Appoints Roee Shahar as Executive Vice President, Commercial

    Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer (following the acquisition of Seagen in December 2023) and Eli Lilly & Company. "Roee further strengthens an Immunome team whose members have designed, developed and commercialized innovative targeted therapies for cancer patients," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.

    10/8/24 8:05:00 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Immunome Inc.

    SC 13G/A - Immunome Inc. (0001472012) (Subject)

    11/14/24 9:00:58 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Immunome Inc.

    SC 13G - Immunome Inc. (0001472012) (Subject)

    11/14/24 1:28:33 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Immunome Inc.

    SC 13G - Immunome Inc. (0001472012) (Subject)

    11/14/24 10:33:51 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care